Activation of mitogen-activated protein kinase signaling and development of papillary thyroid carcinoma in thyroid-stimulating hormone receptor D633H knockin mice

Markus Eszlinger, Alexandra Stephenson, Shideh Mirhadi, Konrad Patyra, Michael F Moran, Moosa Khalil, Jukka Kero and Ralf Paschke

Abstract

Objective: Nonautoimmune hyperthyroidism (NAH) is rare and occurs due to a constitutively activating thyroid stimulating hormone receptor (TSHR) mutation. In contrast to other thyroid nodules, no further evaluation for malignancy is recommended for hot thyroid nodules. In the first model for NAH in mice nearly all homozygous mice had developed papillary thyroid cancer by 12 months of age.

Methods: To further evaluate these mice, whole exome sequencing and phosphoproteome analysis were employed in a further generation of mice to identify any other mutations potentially responsible and to identify the pathways involved in thyroid carcinoma development.

Results: Only three genes (Nrg1, Rrs1, Rasal2) were mutated in all mice examined, none of which were known primary drivers of papillary thyroid cancer development. Wild-type and homozygous TSHR D633H knockin mice showed distinct phosphoproteome profiles with an enrichment of altered phosphosites found in ERK/mitogen-activated protein kinase (MAPK) signaling. Most importantly, phosphosites with known downstream effects included BRAF p.S766, which forms an inhibitory site: a decrease of phosphorylation at this site suggests an increase in MEK/ERK pathway activation. The decreased phosphorylation at BRAF p.S766 would suggest decreased AMP-activated protein kinase (AMPK) signaling, which is supported by the decreased phosphorylation of STIM1 p.S257, a downstream AMPK target.

Conclusion: The modified phosphoproteome profile of the homozygous mice in combination with human literature suggests a potential signaling pathway from constitutive TSHR signaling and cAMP activation to the activation of ERK/MAPK signaling. This is the first time that a specific mechanism has been identified for a possible involvement of TSH signaling in thyroid carcinoma development.

Keywords

- thyroid
- cancer
- hot thyroid nodules
- mouse model

© 2023 the author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

https://creativecommons.org/licenses/by-nc/4.0/
Introduction

Nonautoimmune hyperthyroidism (NAH) is caused by a constitutively activating thyroid stimulating hormone receptor (TSHR) germline mutation. Germline mutations in TSHR lead to sporadic and familial NAH (SNAH, FNNAH) whereas somatic mutations lead to hot thyroid nodules (HTN). Somatic point mutations that constitutively activate the TSHR were first identified in HTN (1). Subsequently, TSHR germline mutations were identified (2). Somatic and germline TSHR mutations show similar gene expression profiles (3). Current evidence suggests that these mutations explain the clinical phenotype of HTN through their activation of the Gs or the Gi and Gq/11 pathway, resulting in a stimulation of proliferation and differentiation/hormone synthesis (4, 5, 6, 7, 8, 9).

At variance with most other thyroid nodules, current textbooks and guidelines assess HTN as a low cancer risk with no further malignancy evaluation recommended (10). To understand the role of TSHR signaling in the development of hyperthyroidism and thyroid growth, a knockin (KI) mouse model harboring a patient-derived TSHR D633H mutation was generated (11). This mutation has been reported 13 times in hot thyroid adenoma and once in thyroid carcinoma (12). Interestingly, this is one of the few activating mutations with a proposed molecular mechanism of TSHR activation: the disruption of a specific H-bonding network formed between the central regions of transmembrane domain 6 and transmembrane domain 7 which has been proposed as essential for maintaining inactivation of the TSHR (13). For the first time, we found that in the TSHR D633H KI mouse model NAH is not as stable as expected but rather is a dynamic condition involving age, sex, and Tshr allele-dependent compensatory mechanisms (11). However, most interestingly, our data strongly suggest that a permanently active TSHR can lead to the malignant transformation of thyrocytes. After 12 months, papillary thyroid carcinoma (PTC) occurred in both heterozygous (HEZ) and homozygous (HOZ) TSHR D633H KI mice with the highest prevalence in HOZ females (11). While the majority of PTCs in humans are typically characterized by a permanently active mitogen-activated protein kinase (MAPK) signaling due to mutations in BRAF or one of the RAS genes (14, 15), no such mutations were found in the PTCs of TSHR D633H KI animals (11). However, increased ERK1/2 and phospho-ERK1/2 staining was found in the mice harboring PTC (11). Together, this suggests involvement of the TSHR through activation of MAPK, in the development of PTC in this model.

Possible mechanisms for a transition of a subset of thyroid adenomas to thyroid carcinomas have repeatedly been discussed (16, 17, 18, 19). To date, 21 case reports for hot thyroid carcinomas have been published (12) and a recent structured meta-analysis demonstrated an OR of 0.45 for malignancy in HTNs suggesting that while the risk is reduced from that of nontoxic nodules, it is higher than previously believed (20). Moreover, graded TSH suppression according to recurrence risk is the backbone of current thyroid cancer recurrence risk reduction strategies (10). We therefore further investigated the TSHR D633H mutation KI mouse model’s genome and phosphoproteome to identify the respective responsible signaling pathway(s) for the evolution of PTCs and the degree to which the TSHR is involved.

The current study provides strong evidence for TSHR’s role in PTC development and suggest that TSHR mutations alone may act as a driver mutation in mice. Furthermore, ERK/MAPK signaling was further implicated and a potential pathway from TSHR activation to MAPK signaling is supported by phosphoproteome data.

Materials and methods
TSHR D633H KI mice, animal husbandry, and genotyping

In the preceding study a KI mouse model was generated harboring the TSHR D633H mutation (11). Mice were housed under controlled conditions (IVC units, 12-h light:12-h darkness, 21 ± 1°C) at the Central Animal Laboratory, University of Turku. Animals were provided access to water and pelleted chow ad libitum (SDS RM-3 (P); Special Diet Service). The chow contained 0.4 mg/kg iodine, which has been previously shown to be sufficient for thyroid function (21). For hormone analysis, blood from the lateral saphenous vein or via cardiac puncture was collected. Animals were sacrificed with CO₂. For the phenotypic characterization, WT littermates were used as controls.

Morphological characterization and hormone measurements

For ten mice from each group (separated by genotype (HOZ/WT) and sex (M/F)), body weight, body length, tail length, and thyroid weight was recorded at sacrifice. A volume of 0.5–1 mL blood was collected, and the serum was separated for serum TSH and total T4 measurement. Each lobe of the thyroid was preserved separately, one as
formalin-fixed, paraffin-embedded (FFPE) blocks, and one lobe was flash frozen in liquid nitrogen.

Total thyroxine (TT4; #DNOV054) serum concentrations were determined using a commercially available enzyme-linked immunosorbent assay (Novatec). Serum TSH levels were analyzed with the Mouse Pituitary Magnetic Bead Panel (#MPTMAG-49K; Merck Millipore) according to the manufacturer’s instructions as previously described (11).

Histology

For nine mice from each group (separated by genotype [HOZ/WT] and sex [M/F]), formalin-fixed (10% formalin in phosphate-buffered saline [PBS]), paraffin-embedded tissue samples were cut using microtome (Leica) into 4 μm sections and stained with hematoxylin and eosin for histological analysis using standard methods. Stained sections were scanned with a Panoramic 250 Flash III Digital Slide Scanner (3D HISTECH). For the classification of thyroid neoplasia, the definition of the World Health Organization on ‘Tumours of the Thyroid and Parathyroid’ was used (22). Histology was examined by two experienced pathologists (Drs Moosa Khalil and Ronald Ghossein) independently from each other as was described for the previous generation of these mice (11).

Study approval

All experiments were authorized by the National Animal Experiment Board of Finland (License number: 10266).

Statistical analysis

GraphPad Prism v7 (GraphPad Software, Inc.) was used for statistical analysis. An unpaired t-test and one-way analysis of variance with Dunnett’s post hoc test and nonparametric Kruskal–Wallis test were used to determine statistical significances. A P-value of <0.05 was set as the limit of statistical significance.

Whole exome sequencing (WES)

Input samples (DNA isolated from thyroid tissue) were normalized to 100 ng and sheared by Covaris to 200 bp. Libraries were prepared using the Agilent SureSelect XT HS Target Enrichment Kit for Illumina, captured in single plex with baits from the Agilent SureSelect XT CD Mouse All Exon V2 kit. The libraries were pooled and sequenced on an Illumina NovaSeq6000 SP flowcell in 2 × 100 cycle configuration using NEB Unique Dual Indices. Small nucleotide variants were called using Illumina Dragen version 07.021.510.3.5.7 using the standard variant caller pipeline against reference genome mm10. Genomic alterations of interest met the following criterion: variants found in DNA from more than one TSHR D633H KI HOZ mouse in >10 reads.

Phosphoproteome analysis

Preparation of phosphopeptide eluates and analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS) using an EASY-nanoLC 1200 system and an Orbitrap Fusion™ Lumos™ Tribrid™ Mass Spectrometer (Thermo Fisher Scientific) is described in Supplementary Methods File 1 (see the section on Supplementary Materials given at the end of this article).

Phosphoproteome normalization

Normalization was performed by using the control bridges per peptide by internal reference scaling (23). Normalization was successful as evidenced by absence of clustering by isobaric label group or TMT experimental group clustering.

Statistical analyses of phosphoproteome data

Phosphoproteome hierarchical clustering and principal component analysis (PCA) were performed on the subset of peptides quantified in all samples by Spearman’s rho clustering method for both rows and columns.

Phosphoproteome intensities are log2 transformed and z-score across respective samples. For sample (columnwise) and protein (rowwise) clustering, Spearman’s rho correlation distance with average linkage was used using Perseus software default parameters. Volcano analysis was performed, where all phosphopeptides detected in at least 70% of samples was compared between the two groups with 0.05 false discovery rate and s0 = 0.1 parameter.

Results

Female TSHR D633H KI mice have lower TSH and higher thyroid weight and exhibit increased PTC prevalence at 12 months of age

Similarly to the previous description (11), the TSH is significantly lower in HOZ TSHR D633H KI males
(P < 0.01) and females (P < 0.001) than their WT littermates (Supplementary Fig. 1A and E). There is no significant difference between total T4 in HOZ and WT in either sex (Supplementary Fig. 1B and F). Body weight is significantly lower in HOZ female mice than WT (P < 0.01) (Supplementary Fig. 1C and G). Thyroid weight is significantly higher in both HOZ males (P < 0.001) and females (P < 0.001) compared to WT (Supplementary Fig. 1D and H). In nine thyroids from HOZ females for which slides from throughout FFPE block were reviewed, eight were positive for PTC (88%); in nine male HOZ samples for which the slides from throughout the FFPE block were reviewed, five were positive for PTC (55%) (Supplementary Fig. 2).

**WES uncovers no further causative mutations**

WES was performed on one lobe of five female HOZ mice and three female WT mice, respectively. All five HOZ mice had confirmed PTC in the contralateral FFPE preserved lobe. In a first filtering step, the sequence variants identified in the HOZ mice were compared against the sequence variants detected in the WT mice and overlapping variants were excluded. In a second filtering step, the HOZ mice specific variants were filtered to exclude intronic variants, silent variants, ncRNAs and variants with less than ten variant reads resulting in 330 remaining variants. 13 variants were found in more than one mouse (Fig. 1). First, the introduced TSHR mutation p.D633H could be detected in all five analyzed mouse samples. In addition, the Nacad frameshift mutation p.P37fs, the Nrg variant p.T463N and four different Rs1 variants were also detected in the five analyzed mouse samples (Table 1, Fig. 1). Furthermore, in four out of five mice the Rasal2 variant p.E453K was detected. While in three out of five mice samples variants were detected in Kpna4, Narf and Net1, variants in Ddias, Thap1, Ankrd36, Pgk2, and Pou3f3 were detected in two mice each.

The involvement of the 13 mutated genes in carcinogenesis was evaluated using COSMIC database for humans, and candidate cancer gene database (CCGD) for mice (Table 1) (24, 25). According to CCGD, for none of the mutant genes a mouse model could be identified that would support a role in thyroid cancer (Table 1). Furthermore, using the COSMIC database we identified the percentage of human thyroid samples with detected variants in the genes identified by WES in our mice. The highest prevalence in thyroid samples was reported for TSHR.
Phosphoproteome profiling was performed for 18 HOZ mice (eight females, ten males) and 18 WT mice (eight females, ten males), respectively. Of the 3900 phosphopeptides quantified, majority were serine (S) followed by threonine (T) and finally tyrosine (Y) residues (Fig. 2A). Based on an unbiased hierarchical Spearman’s rho clustering of phosphopeptides, two major clusters are formed. One with 17 WT and one HOZ mouse, the other including 17 HOZ and one WT mouse (Fig. 2B). Of the 36 samples analyzed, all but two male samples (one WT and one HOZ) clustered within their genotype (Fig. 2B). Applying a PCA including both genotype and sex confirms the findings of the hierarchical clustering demonstrating a very clear separation of mice into WT and HOZ clusters (Fig. 2C). Moreover, among HOZ samples a clear distinction between sex is also seen, but it is noticeable that the male HOZ mice show significantly weaker differences compared to the WT mice than the female HOZ mice (Fig. 2B and C). This can be due to baseline differences that exist between males and females for TSH pathway.

To identify these baseline sex differences, the phosphorylation patterns of phosphopeptides of WT males and females were compared to one another. Significantly different phosphorylation patterns between male and female mice could be identified for 142 phosphopeptides (Supplementary Table 1). Phosphorylation of thyroglobulin was significantly lower in WT males compared to WT females but at a similar level in WT females compared to female HOZ mice (Fig. 2D). The same analysis was completed for HOZ mice without any significantly different phosphosites identified.

Pathway enrichment analysis emphasizes changes in MEK/ERK signaling

148 significantly differential phosphosites between all WT and HOZ samples were identified using volcano analysis (Fig. 3A). Based on these phosphosites a list of significantly enriched pathways was generated using Ingenuity Pathway Analysis tool (Qiagen) (Fig. 3B). The same analyses were performed sex-specifically for females only
identifying 268 significantly differential phosphosites between WT and HOZ samples (Fig. 3C and D) and males only identifying one significant differential phosphosite (CLIP4) between WT and HOZ samples (Supplementary Fig. 3), respectively.

The following pathways of interest based on their known association with thyroid or thyroid cancer signaling were selected from the list of significantly enriched pathways: ERK/MAPK signaling, protein kinase A signaling, insulin receptor signaling, Rho family GTPases, and molecular mechanisms of cancer. The signaling pathways were overlaid with phosphosites significantly enriched in female HOZ mice (Fig. 4, Supplementary Figs. 4, 5, 6, and 7). The known upstream and downstream effects of these phosphosites were summarized for ERK/MAPK signaling (Table 2). Most importantly, phosphosites with known downstream effects included BRAF p.S766 (Fig. 5).
Discussion

We have shown that the majority of mice with constitutive TSHR mutation p.D633H develop PTC. While the molecular etiology for human PTC is well understood, in our model no mutations in the known causative genes were detected. Phosphoproteome analysis demonstrated a clear separation based on differentially phosphorylated proteins between female WT and HOZ mice. While an unbiased pathway analysis found several significantly enriched pathways, the increased ERK/MAPK signaling in HOZ female mice is in line with previous findings (11) and clearly demonstrates a potential link between TSHR and MAPK signaling.

Female TSHR D633H KI mice have a more severe hyperthyroidism and carcinoma phenotype

In this generation of mice, HOZ mice of both sexes demonstrate subclinical hyperthyroidism: decreased TSH without accompanying increased T4 (Supplementary Fig. 1) in contrast to the previous generation’s overt hyperthyroidism in females (11). The comparison of TSH levels between male and female mice revealed higher TSH levels in male mice, which is comparable to the previous generation of mice (11). In contrast, male and female mice are characterized by comparable total T4 levels, which are slightly higher compared to the previous generation of mice (with exception of the female HOZ mice) (11).

Table 2  ERK/MAPK pathway enriched phosphopeptides in homozygous mice and their known upstream/downstream effectors.

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Entrez gene name</th>
<th>Phosphosite</th>
<th>Upstream</th>
<th>Downstream</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRAF</td>
<td>B-Raf proto-oncogene, serine-threonine kinase</td>
<td>S766</td>
<td>AMPKA1</td>
<td>Cell growth inhibited</td>
</tr>
<tr>
<td>CRK</td>
<td>CRK proto-oncogene, adaptor protein</td>
<td>S43</td>
<td>Uncharacterized</td>
<td>Uncharacterized</td>
</tr>
<tr>
<td>CRKL</td>
<td>CRK-like proto-oncogene, adaptor protein</td>
<td>S107</td>
<td>Uncharacterized</td>
<td>Uncharacterized</td>
</tr>
<tr>
<td>ITGA1</td>
<td>Integrin subunit alpha 1</td>
<td>Y715</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>PIK3R4</td>
<td>Phosphoinositide-3-kinase regulatory subunit 4</td>
<td>S18</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>PPP1R7</td>
<td>Protein phosphatase 1 regulatory subunit 7</td>
<td>S24</td>
<td>PLK1</td>
<td>Uncharacterized</td>
</tr>
<tr>
<td>PPP1R14A</td>
<td>Protein phosphatase 1 regulatory inhibitor subunit 14A</td>
<td>S134</td>
<td>Uncharacterized</td>
<td>Uncharacterized</td>
</tr>
<tr>
<td>PRKAR1A</td>
<td>Protein kinase CAMP-dependent type I regulatory subunit alpha</td>
<td>S77</td>
<td>Metastatic potential</td>
<td>Molecular association regulation</td>
</tr>
<tr>
<td>PRKAR2A</td>
<td>Protein kinase CAMP-dependent type II regulatory subunit alpha</td>
<td>T101</td>
<td>Uncharacterized</td>
<td>Uncharacterized</td>
</tr>
<tr>
<td>PXN</td>
<td>Paxillin</td>
<td>S321</td>
<td>Uncharacterized</td>
<td>Uncharacterized</td>
</tr>
<tr>
<td>RPS6KA4</td>
<td>Ribosomal protein S6 kinase A4</td>
<td>S681</td>
<td>Uncharacterized</td>
<td>Uncharacterized</td>
</tr>
<tr>
<td>TNN1</td>
<td>Talin 1</td>
<td>S1328</td>
<td>Uncharacterized</td>
<td>Uncharacterized</td>
</tr>
</tbody>
</table>
TSH differences among sexes have been reported in mice but with high variability depending on the mice strain. Therefore, one could speculate that a particular mice strain background could be a possible reason for the higher percentage of PTCs in females (88% vs 55% in males), which was also observed in the previous generation (females 88% vs males 71%). However, also in humans, hyperthyroidism and thyroid cancer occur about three times more often in women than in men.

The decreased body weight in females may reflect a more severe hyperthyroid phenotype, consistent with the previously described generation (Supplementary Fig. 1C and G) (11). The higher PTC incidence in females (Fig. 2) is consistent with the increased degree of affectedness of females in this model that was previously observed and also fits with the fact that both benign and malignant thyroid disorders affect women three to four times more than men (11, 26, 27, 28). The baseline differences in phosphorylation observed in the WT mice, namely, the lower baseline phosphorylated thyroglobulin levels in males, could explain the differences seen in this model. Sex differences in thyroglobulin serum concentrations are not observed in humans (29, 30).

TSHR variant as a driver mutation for thyroid carcinoma

Whole-exome sequencing (WES) was performed on female mice based on the higher frequency of PTC in female mice and the subjective observation that PTCs in female mice were larger and constituted more of the thyroid. Based on the morphological data indicating a relatively consistent phenotype among TSHR D633H KI HOZ mice, our focus for WES data analysis was on genes mutated in more than one mouse (Table 1). Using the COSMIC database, we assessed the prevalence of the variants detected by WES in 1040 human thyroid carcinomas. In addition, a CCGD search was done to rule out a variant that is mouse-specific in inducing thyroid cancer (24, 25). There were no published mice data suggesting involvement of any of the top twenty genes in thyroid carcinoma according to CCGD nor were any of these genes mutated in more than 15% of thyroid cancer samples in the COSMIC database. A literature search for cases of thyroid carcinoma with these variants was performed to better understand their role in carcinogenesis.

Nacad, Nrg1 and Rrs1 were mutated in all five HOZ samples submitted for WES (Fig. 1) and had a respective variant prevalence in human thyroid cancer of 4%, 0.4% and 0.9% according to the COSMIC database, respectively. Since all variants detected in HOZ mice were filtered for variants detected in a pool of three WT mice, a mice strain specific occurrence of the identified variants can be excluded. In contrast, variants detected in all five HOZ mice could be the result of a common second hit mechanism induced by hyperproliferation of thyrocytes.
in the HOZ mice. Nrg1 is an epidermal growth factor-like family member with many roles including cell signaling mediation and organ growth and development. While the p.T463N Nrg1 variant detected in this mouse model has not previously been described, increased NRG1 expression in humans showed moderate association with a more aggressive course of BRAF mutation positive PTCs (31, 32).

In humans, RRS1 gene expression is significantly increased in thyroid carcinoma compared to paired pericarcinous tissues and PTC cells in culture showed reduced cell proliferation, cell cycle and increased apoptosis when RRS1 was knocked out (33).

Limited data exist for Ncad, however, as it is known to be primarily expressed in the brain, followed by the ovaries, adrenal glands and testis, with very low expression in the thyroid it’s involvement in the carcinoma phenotype is unlikely (34).

Rasal2, the inhibitory regulator of the Ras cAMP pathway with a known role in breast and lung cancer (35, 36), Ddias, a DNA damage induced apoptosis suppressor which is upregulated by ERK signaling (37), Kpna4 an oncogene with a role in PTC cell proliferation and invasion shown to be overexpressed in PTC cells (38), and Thap1, also shown to be overexpressed in PTC cells may all have a role in PTC development. However, variants in these genes were found only in a subset of mice. As the phenotype across all five female mice is consistent, this suggests that none of these genes are primarily responsible for the carcinoma in our model, although likely may play secondary roles in some mice as described above for Nrg1 and Rrs1.

For the remaining genes mutated in less than 5 mice there is no evidence in the literature for a role in thyroid carcinoma.

Based on our analysis, there are thus no obvious primary causative mutations in addition to the TSHR mutation in these TSHR D633H KI mice. While a potential secondary role in the development of PTC for one or more of these additional variants detected by WES, particularly Nrg1 and Rrs1 could be possible, there is no obvious candidate for a primary driver mutation other than the TSHR mutation.

In humans, TSHR mutations were found in 2% of COSMIC database thyroid carcinoma samples (Database accessed February 11 2022; search query TSHR). While this is a low number, the prevalence of hot thyroid carcinomas is equally low. As of 2020, there were 21 published cases of human thyroid carcinoma with TSHR mutations. Of these 21 cases, three reported further mutations (1 KRAS, 1 NRAS and 1 PAX8-PPARG), seven have reported negative results for analysis of additional mutations, although the further genes assessed vary. Histologic diagnoses were 13 FTC, six PTC, one Hurthle cell thyroid cancer, and one insular thyroid cancer ((12), https://tsh-receptor-mutation-database.org). Also, TSHR mutations have been suggested to be associated with an increased cancer risk (39). Taken together, the WES results of the mice thyroids without a detection of a likely driver mutation in addition to the introduced TSHR mutation, and the molecular data reported for hot thyroid carcinomas in humans support the hypothesis that the mechanism of PTC formation in our mouse model is likely novel and caused by TSHR mutation.

Sex differences

The reasons for the 3-4-fold increased rates of benign and malignant thyroid disorders in women is not well understood (11, 26, 27, 28). In an attempt to unravel some of the differences in signaling, phosphorylation profiles were compared across sexes in WT and in HOZ mice. Interestingly, WT males showed a lower thyroglobulin phosphorylation compared to WT females but at a similar level as the HOZ mice of both sexes. In fact, comparing male HOZ and WT mice revealed only one significantly different phosphopeptide (CLIP4) based on t-test FDR <0.05. CLIP4 showed the same phosphorylation pattern when comparing female HOZ and WT mice. CLIP4 is located in an intracellular membrane-bounded organelle and is predicted to be involved in cytoplasmic microtubule organization. More research is needed to elucidate the reasons for sex differences in this model and in human thyroid disorders.

The connection between TSHR and MAPK signaling

Many cancers have associated dysregulated kinase signaling whether this is through kinase overexpression, mutations in kinase genes, or defects in counterregulatory mechanisms (40, 41). While genomic changes such as a TSHR mutation in a carcinoma without any other driver mutations are the first step to understanding the mechanism of carcinogenesis, it is essential to understand the consequences in signaling in order for this information to inform the etiology of thyroid cancer in general. For this reason, following our WES result, phosphoproteome analysis was performed.

TSHR signaling via cAMP is increased by the D633H KI mutation, as evidenced by the 5.4-fold increase in basal cAMP signaling for the TSHR (11, 13, 42). Furthermore,
CAMP signaling has been shown to activate MAPK signaling (43, 44). Within the BRAF protein, a central component of the MAPK pathway, serine-729 (p.S729) forms an inhibitory site: when phosphorylation at this site occurs by AMPK, it has been shown to inhibit the phosphorylation/activation of downstream MEK/ERK (45, 46). Vice versa, a decrease of phosphorylation at this site suggests an increase in MEK/ERK pathway activation. Interestingly, the homologous position of the human BRAF p.S729 in mice, Braf p.S766, is characterized by decreased phosphorylation in HOZ mice (Table 2, Fig. 5). While further downstream ERK/MEK phosphopeptides were not identified or quantified by this analysis, phosphorylated ERK1/2 characterized by immunohistochemistry was seen in the carcinoma lesions of this model (11). The decreased phosphorylation at Braf p.S766 in HOZ females would suggest decreased AMPK signaling which is supported by the decreased phosphorylation of STIM1 p.S257, a downstream target of AMPK (47). Furthermore, AMPK inactivation downstream of TSHR has been suggested multiple times (48, 49, 50, 51) and evidence of AMPK inhibition by cAMP signaling (53) offers a direct mechanism for the signaling changes found in this model (Fig. 6).

Further supporting the role of aberrant cAMP signaling is differential Prkar1a phosphorylation at p.S77 (Table 2, Fig. 5). This is a regulatory subunit of protein kinase A (PKA), responsible for regulating activity downstream of PKA in response to cAMP. While the downstream effects of phosphorylation at this site are not known, alterations in PKA activity can lead to numerous different effects based on a variety of factors including cAMP basal levels which are higher than WT in this model (11, 54). Upstream metastatic potential has also been observed (55). In humans, PRKAR1A mutations are found in more than half of patients with Carney Complex (CNC) (56). This condition results in increased cAMP signaling and also demonstrates rare PTCs in addition to benign HTN (57). Based on these findings we propose a signaling pathway for the development of thyroid cancer in our mouse model as summarized in Fig. 6.

In our previous study (11) we speculated that the simultaneous activation of Gq/11, in addition to Gs could be an important player in tumor formation in the TSHR D633H KI mouse model because α1B-adrenergic receptor mutant mice show malignant transformation of thyrocytes along with activation of both Gs and Gq/11 signaling pathways (58). Nevertheless, by immunohistochemistry, we also saw an increased phosphorylation of ERK1/2 in the PTC areas of the TSHR D633H KI mice (11), which argues for an activation of the MAPK signaling pathway. Indeed, TSH signaling can converge toward a MAPK growth signal, for example via Gs, EPAC and/or RAP1B as shown previously in thyrocyte models (43, 44). Despite in a different way, the current findings support the latter, a link between Gs signaling and MAPK activation. Overall, based on the previous data showing potential relevance of Gq/11 signaling (for which we found no evidence at the phosphoproteome level) and on our previous and current data showing a specific phosphorylation pattern supporting a Gs - MAPK link, we can speculate that both arms of TSHR signaling, via Gs and Gq/11, are important for the malignant transformation in the PTC areas seen in our mouse model.

We acknowledge that in addition to our descriptive phosphoproteome analyses further functional studies are needed to precisely elaborate the mechanism behind the molecular patterns we have observed in this study.

Figure 6
Proposed signaling pathway leading to increased MEK/ERK signaling in TSHR D633H KI mouse model.
It would be interesting to investigate if the effects on AMPK/BRAF/MEK/ERK pathway are directly caused by TSHR hyperactivation through cAMP or if the metabolic alterations induced by the hyperthyroid state could play a role as well, since many different signaling pathways influenced by metabolic changes can modulate AMPK activity and signaling.

It is not the first time TSHR signaling has been implicated in thyroid cancer. TSHR signaling has been suggested to have a role in a genetic predisposition to PTC (59). High-normal serum TSH is associated with a higher risk for differentiated thyroid cancer in thyroid nodule patients (60) and thyroid cancer in patients with thyroid nodules is predicted by baseline serum TSH concentrations (61). Furthermore, there are 21 published cases of TSHR mutation positive hot thyroid carcinomas (2) and TSHR signaling is implicated in the development of thyroid carcinoma as well as severity of thyroid carcinoma phenotype (62, 63, 64). Finally, our mouse data demonstrate a signaling pathway through which Tshr signaling in mice could lead to malignancy via activation of the MAPK pathway downstream of cAMP.

In summary, these data impressively demonstrate a key role of the TSHR-cAMP pathway in Braf-induced PTC initiation in mice, and are consistent with the association of TSH levels with thyroid cancer incidence in humans (61).

Conclusions

TSHR D633H KI mice develop PTC while maintaining a subclinical hyperthyroidism phenotype. While the molecular etiology for PTC in humans is generally considered to be well understood, no mutation in known driver genes were detected in the mouse PTCs. Nevertheless, variants that may contribute to a multi-hit model together with the TSHR mutation were identified by WES. Most importantly, phosphoproteome analysis revealed a potential link between Tshr signaling and the MAPK pathway in mice. We identified decreased phosphorylation of Braf p.S766 as the likely specific link by which activation of the cAMP pathway in TSHR D633H mutation KI mice leads to increased MEK/ERK signaling and hence a high incidence of PTCs.

Supplementary materials

This is linked to the online version of the paper at https://doi.org/10.1530/ETJ-23-0049.

Declaration of interest

ME reports: no conflict of interest; AS reports: no conflict of interest; SM reports: no conflict of interest; KP reports: no conflict of interest; MM reports: no conflict of interest; MK reports: no conflict of interest; JK reports: no conflict of interest; RP reports: advisory board honoraria from Bayer and Eisai; Funding statement.

Funding

The study was funded by a Laura Linders Grant.

Author contribution statement

ME: conceptualization, formal analysis, writing – original draft, writing – review & editing; AS: investigation, formal analysis, writing – original draft; SM: methodology, investigation, formal analysis, KP: investigation; MM: methodology, supervision; MK: investigation; JK: resources, supervision; RP: conceptualization, resources, supervision, writing – review & editing.

Acknowledgements

We thank Ronald Ghossein for his evaluation of the PTC samples.

References


Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Facini E, Randolph GW, Sawka AW, Schlumberger M, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid* 2016 26 1–133. ([https://doi.org/10.1089/thy.2015.0020](https://doi.org/10.1089/thy.2015.0020))


Rahbari R, Zhang L & Kebebew E. Thyroid cancer gender disparity. *Future Oncology* 2010 6 1771–1779. ([https://doi.org/10.2217/ fon.10.127](https://doi.org/10.2217/ fon.10.127))


Lee ML, Chen GG, Vliantis AC, Tse GM, Leung BC & Van Hasselt CA. Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-XX. *Cancer Journal* 2005 11 113–121. ([https://doi.org/10.1097/00130404- 200503000-00006](https://doi.org/10.1097/00130404-200503000-00006))


Li N & Li S. RASL2 promotes lung cancer metastasis through epithelial–mesenchymal transition. *Biochemical and Biophysical Research Communications* 2014 455 358–362. ([https://doi.org/10.1016/j.bbrc.2014.11.020](https://doi.org/10.1016/j.bbrc.2014.11.020))


© 2023 the author(s)


61 Boelaert K. The association between serum TSH concentration and thyroid cancer. Endocrine-Related Cancer 2009 16 1065–1072. (https://doi.org/10.1677/ERC-09-0350)


Received 11 March 2023

Accepted 30 August 2023

Available online 1 September 2023

Version of Record published 3 October 2023